### WHAT IS CLAIMED IS:

# 1. A compound of the formula (I):

 $R_n$   $NH_2$  N  $R_2$   $X-O-R_1$  X

10

5

wherein:

X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-;

 $\mathbf{R}_1$  is selected from the group consisting of:

-heteroaryl;

-heterocyclyl;

15

20

-R<sub>4</sub>- heteroaryl; and

-R4-heterocyclyl;

 $\mathbf{R_2}$  is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

25

-alkyl-Y-alkenyl;

-alkyl-Y-aryl; and

- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

30

-halogen;

 $-N(R_3)_2;$  $-CO-N(R_3)_2;$ -CO- $C_{1-10}$  alkyl; -CO-O-C<sub>1-10</sub> alkyl;  $-N_3$ ; 5 -aryl; -heteroaryl; -heterocyclyl; -CO-aryl; and -CO-heteroaryl; 10

R4 is alkyl or alkenyl, which may be interrupted by one or more -Ogroups;

each R<sub>3</sub> is independently H or C<sub>1-10</sub> alkyl; each Y is independently -O- or -S(O)0-2-;

n is 0 to 4; and

each  ${\bf R}$  present is independently selected from the group consisting of  $C_{1\text{-}10}$ alkyl,  $C_{1-10}$  alkoxy, hydroxy, halogen and trifluoromethyl; or a pharmaceutically acceptable salt thereof.

20

30

15

- A compound or salt of claim 1 wherein R<sub>1</sub> is -(CH<sub>2</sub>)<sub>0-3</sub>-heteroaryl. 2.
- A compound or salt of claim 2 wherein the heteroaryl is selected from the group 3. consisting of 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-thiazolyl, 2-pyrimidinyl, 4-pyrimidinyl, 4triazolyl, 2-benzofuranyl, 2-indolyl, 3-carbazolyl, 2-furanyl, 4-isoquinolinyl, 4-isoxazolyl, 25 and 4-pyrazolyl
  - A compound or salt of claim 1 wherein X is -CH(alkyl)(alkyl)- wherein the alkyl 4. groups can be the same or different.

A compound or salt of claim 1 wherein X is -CH2-CH2-. 5.

- A compound or salt of claim 1 wherein X is -CH(C<sub>2</sub>H<sub>5</sub>)(CH<sub>2</sub>)-. 6.
- A compound or salt of claim 1 wherein R<sub>2</sub> is H. 7.
- A compound or salt of claim 1 wherein R2 is alkyl. 5 8.
  - A compound or salt of claim 1 wherein R<sub>2</sub> is -alkyl-O-alkyl. 9.
  - A compound of the formula (II) 10.

$$R_{n}$$
 $NH_{2}$ 
 $NH_{2}$ 
 $N$ 
 $R_{2}$ 
 $X-O-(CH_{2})_{1-10}-C\equiv C-R_{10}$ 
(II)

wherein:

X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-;

15

 $\mathbf{R}_{10}$  is selected from the group consisting of heteroaryl and heterocyclyl;

 $\mathbf{R_2}$  is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

20

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

-alkyl-Y-alkenyl;

25

-alkyl-Y-aryl; and

-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH; -halogen;  $-N(R_3)_2;$  $-CO-N(R_3)_2;$ -CO- $C_{1-10}$  alkyl; 5 -CO-O- $C_{1-10}$  alkyl;  $-N_3$ ; -aryl; -heteroaryl; -heterocyclyl; 10 -CO-aryl; and -CO-heteroaryl; n is 0 to 4; each R<sub>3</sub> is independently H or C<sub>1-10</sub> alkyl; each Y is independently -O- or -S(O)<sub>0-2</sub>-; and 15 each R present is independently selected from the group consisting of C<sub>1-10</sub> alkyl, C<sub>1-10</sub> alkoxy, hydroxy, halogen and trifluoromethyl;

20 11. A compound or salt of claim 10 wherein R<sub>10</sub> is selected from the group consisting of heteroaryl and substituted heteroaryl.

or a pharmaceutically acceptable salt thereof.

- 12. A compound of claim 11 wherein the heteroaryl is selected from the group consisting of 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-thiazolyl, 4-pyrazolyl, 3-furanyl, 2-thienyl, and 2-pyrimidinyl.
  - 13. A compound or salt of claim 10 wherein X is -CH(alkyl)(alkyl)-, wherein the alkyl groups can be the same or different.
- 30 14. A compound or salt of claim 10 wherein X is -CH<sub>2</sub>-CH<sub>2</sub>-.

25

15. A compound or salt of claim 10 wherein X is -CH(C<sub>2</sub>H<sub>5</sub>)(CH<sub>2</sub>)-.

- 16. A compound or salt of claim 10 wherein R<sub>2</sub> is H, alkyl, or alkyl-O-alkyl.
- 17. A compound selected from the group consisting of:

```
5
                                                                                       1-(2-\{[3-(\mathrm{isoquinolin}-4-\mathrm{yl})-2-\mathrm{propynyl}] \\ \text{oxy}\} \\ \text{ethyl})-1\\ H-\mathrm{imidazo}[4,5-c] \\ \text{quinolin}-4-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{propynyl}] \\ \text{oxy} \\ \text{ethyl}(-2-\mathrm{yl})-1\\ H-\mathrm{imidazo}[4,5-c] \\ \text{quinolin}-4-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{yl})-2-\mathrm{yl}(-2-\mathrm{y
                                                                                        amine;
                                                                                         1-(2-\{[3-(1,3-\text{thiazol}-2-\text{yl})-2-\text{propynyl}] \text{oxy}\} \text{ ethyl})-1\\ H-\text{imidazo}[4,5-c] \text{ quinolin-4-lembers}
                                                                                          amine;
                                                                                          1-\{2-[3-(1H-4-pyrazolyl)propoxy]ethyl\}-1H-imidazo[4,5-c]quinolin-4-amine;
10
                                                                                           1-[2-(3-pyrimidin-2-ylpropoxy)ethyl]-1H-imidazo[4,5-c]quinolin-4-amine;
                                                                                           1-[2-(3-pyridin-4-ylpropoxy)ethyl]-1H-imidazo[4,5-c]quinolin-4-amine;
                                                                                             1-[2-(3-pyridin-2-ylpropoxy)ethyl]-1H-imidazo[4,5-c]quinolin-4-amine;
                                                                                             1-\{2-[3-(1,3-\text{thiazol}-2-\text{yl})\text{propoxy}]\text{ethyl}\}-1H-\text{imidazo}[4,5-c]\text{quinolin-4-amine};
                                                                                             1-[2-(3-pyridin-3-ylpropoxy)ethyl]-1H-imidazo[4,5-c]quinolin-4-amine;
 15
                                                                                             1-[2-(3-pyrimidin-5-ylpropoxy)ethyl]-1H-imidazo[4,5-c]quinolin-4-amine;
                                                                                              1-\{2-[(1-benzyl-1H-1,2,3-triazol-4-yl)methoxy]ethyl\}-1H-imidazo[4,5-triazol-4-yl]methoxy]ethyl\}
                                                                                               c]quinoline-4-amine;
                                                                                               1-\{2-[(1-benzyl-1H-1,2,3-triazol-5-yl)methoxy]ethyl\}-1H-imidazo[4,5-triazol-5-yl)methoxy]ethyl\}
                                                                                               clquinoline-4-amine;
    20
                                                                                                1-[2-(\{1-[(phenylsulfanyl)methyl]-1H-1,2,3-triazol-4-yl\}methoxy) ethyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyllanylsulfanylsulfanylsulfanylsulfanylsulfanylsulfanylsulfanylsulfanylsulfanylsulfanylsulfanylsulfanylsulfanylsulfanylsulfanylsulfanylsulfanylsulfanylsulfanylsulfanylsulfanylsulfanylsulfanylsulfanylsulfanylsulfanylsulfanylsulfanylsulfa
                                                                                                 imidazo[4,5-c]quinoline-4-amine;
                                                                                                 1-[2-(\{1-[(phenylsulfanyl)methyl]-1H-1,2,3-triazol-5-yl\}methoxy)ethyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyl]-1H-1+[(phenylsulfanyl)methyll]-1H-1+[(phenylsulfanyl)methyll]-1H-1+[(phenylsulfanyl)methyll]-1H-1+[(phenylsulfanyl)methyll]-1H-1+[(phenylsulfanyl)methyll]-1H-1+[(phenylsulfanyl)methyll]-1H-1+[(phenylsulfanyl)methyll]-1H-1+[(phenylsulfanyl)methyll]-1H-1+[(phenylsulfanyl)methyll]-1H-1+[(phenylsulfanyl)methyll]-1H-1+[(phenylsulfanyl)methyll]-1H-1+[(phenylsulfanyl)methyll]-1H-1+[(phenylsulfanyl)methyll]-1H-1+[(phenylsulfanyl)methyll]-1H-1+[(phenylsulfanyl)methyll]-1H-1+[(phenylsulfanyl)methyll]-1H-1+[(phenylsulfanyl)methyll]-1H-1+[
                                                                                                  imidazo[4,5-c]quinoline-4-amine;
                                                                                                  1-[2-(benzo[b]furan-2-ylmethoxy)ethyl]-1H-imidazo[4,5-c]quinolin-4-amine;
       25
                                                                                                    1-[2-(pyridin-3-ylmethoxy)ethyl]-1H-imidazo[4,5-c]quinolin-4-amine;
                                                                                                    1-[2-(pyridin-2-ylmethoxy)ethyl]-1H-imidazo[4,5-c]quinolin-4-amine;
                                                                                                    1-[2-(pyridin-4-ylmethoxy)ethyl]-1H-imidazo[4,5-c]quinolin-4-amine;
                                                                                                    1-\{2-[(3,5-dimethylisoxazol-4-yl)methoxy]ethyl\}-1H-imidazo[4,5-c]quinolin-4-
                                                                                                     amine;
         30
```

amine;

 $1-(2-\{[3-(\mathrm{pyrimidin-}2-\mathrm{yl})-2-\mathrm{propynyl}] \text{oxy}\} \text{ ethyl})-1\\ H-\mathrm{imidazo}[4,5-c] \text{ quinolin-}4-\mathrm{yl}]$ 

```
1-(2-\{[3-(pyrid-4-yl)-2-propynyl]oxy\}ethyl)-1\\ H-imidazo[4,5-c]quinolin-4-amine;
                                                                 1-(2-\{[3-(fur-3-yl)-2-propynyl]oxy\}\ ethyl)-1\\ H-imidazo[4,5-c]\ quinolin-4-amine;
                                                                 4-\{3-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]-propyn-1-yl\}
                                                                  thiophen-2-ylcarboxaldehyde;
                                                                   1-(2-\{[3-(pyrid-2-yl)-2-propynyl]oxy\}ethyl)-1H-imidazo[4,5-c]quinolin-4-amine;
  5
                                                                   1-\{2-\mathsf{methyl-1-[(pyrid-2-yloxy)methyl]propyl}\}-1\\ H-\mathsf{imidazo[4,5-}c] \\ \mathsf{quinoline-4-yloxy}
                                                                   amine;
                                                                     1-\{1-[(pyrid-2-yloxy)methyl]propyl\}-1H-imidazo[4,5-c]quinoline-4-amine;
                                                                     1-[2-(9H-carbazol-3-yloxy)propyl]-1H-imidazo[4,5-c]quinolin-4-amine;
                                                                      1-\{2-[(3-thien-2-ylprop-2-ynyl)oxy]ethyl\}-1H-imidazo[4,5-c]quinolin-4-amine;
10
                                                                       1-\{2-[(1-methyl-1H-indol-2-yl)methoxy]ethyl\}-1H-imidazo[4,5-c]quinolin-4-
                                                                        amine;
                                                                       1-[2-(3-thien-2-ylpropoxy)ethyl]-1H-imidazo[4,5-c]quinolin-4-amine;
                                                                        2-methyl-1-[2-(3-pyridin-3-ylpropoxy)ethyl]-1H-imidazo[4,5-c]quinoline-4-amine;
                                                                         2-butyl-1-[2-(3-pyridin-3-ylpropoxy)ethyl]-1H-imidazo[4,5-c]quinoline-4-amine;
  15
                                                                         1-[2-(tetrahydrofuran-2-ylmethoxy)propyl]-1H-imidazo[4,5-c]quinolin-4-amine;
                                                                          1-\{2-[(5-chloro-1-benzothien-3-yl)methoxy] propyl\}-1 \\ H-imidazo[4,5-c] quinolin-4-thereof a superior of the property of the
                                                                            amine;
                                                                            1-\{2-[(3-nitropyridin-2-yl)oxy]propyl\}-1H-imidazo[4,5-c]quinolin-4-amine;
                                                                            1-(2-methyl-1-\{[(3-nitropyridin-2-yl)oxy]methyl\}propyl)-1\\ H-imidazo[4,5-yl]oxyl-1-(2-methyl-1-4)[(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxyl-1-4][(3-nitropyridin-2-yl)oxy
     20
                                                                             c]quinolin-4-amine;
                                                                             1-(1-\{[(5-chloro-1-benzothien-3-yl)methoxy]methyl\}-2-methylpropyl)-1 \\ H-(1-\{[(5-chloro-1-benzothien-3-yl)methoxy]methyl\}-2-methylpropyl)-1 \\ H-(1-\{[(5-chloro-1-benzothien-3-yl)methoxy]methyl\}-2-methylpropyl)-1 \\ H-(1-\{[(5-chloro-1-benzothien-3-yl)methoxy]methyl\}-2-methylpropyl)-1 \\ H-(1-\{[(5-chloro-1-benzothien-3-yl)methoxy]methyl\}-2-methylpropyl)-1 \\ H-(1-\{[(5-chloro-1-benzothien-3-yl)methoxy]methyl\}-2-methylpropyl)-1 \\ H-(1-\{[(5-chloro-1-benzothien-3-yl)methoxy]methyl\}-2-methylpropyl)-1 \\ H-(1-\{[(5-chloro-1-benzothien-3-yl)methoxy]methylpropyl)-1 \\ H-(1-\{[(5-chloro-1-benzothien-3-yl)methoxy]methylpropyl)-1 \\ H-(1-\{[(5-chloro-1-benzothien-3-yl)methoxy]methylpropyl)-1 \\ H-(1-\{[(5-chloro-1-benzothien-3-yl)methoxy]methylpropyl)-1 \\ H-(1-\{[(5-chloro-1-benzothien-3-yl)methylpropyl]methylpropyl)-1 \\ H-(1-\{[(5-chloro-1-benzothien-3-yl)methylpropyl]methylpropyl]methylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropylpropyl
                                                                              imidazo[4,5-c]quinolin-4-amine;
                                                                             2-(2-methoxyethyl)-1-[2-(3-pyridin-3-ylpropoxy)ethyl]-1\\ H-imidazo[4,5-methoxyethyl]-1
                                                                               c]quinolin-4-amine; and
        25
                                                                               2-methyl-1-[2-(3-pyridin-3-ylpropoxy)ethyl]-6,7,8,9-tetrahydro-1H-imidazo[4,5-
                                                                                c]quinolin-4-amine;
                                                                               or a pharmaceutically acceptable salt thereof.
```

## 18. A compound of the formula (III)

$$R_n$$
 $NH_2$ 
 $N$ 
 $R_2$ 
 $X-O-R_1$ 
(III)

5

15

wherein:

X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-;

 $\mathbf{R}_1$  is selected from the group consisting of:

-heteroaryl;

-heterocyclyl;

10 -R<sub>4</sub>- heteroaryl; and

-R<sub>4</sub>-heterocyclyl;

R<sub>2</sub> is selected from the group consisting of:

-hydrogen;

-alkyl;

......

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

-alkyl-Y-alkenyl;

-alkyl-Y-aryl; and

- alkyl or alkenyl substituted by one or more substituents selected

from the group consisting of:

-OH;

25

20

-halogen;

 $-N(R_3)_2;$ 

 $-CO-N(R_3)_2;$ 

-CO-C<sub>1-10</sub> alkyl;

-CO-O-C<sub>1-10</sub> alkyl;

 $-N_3$ ;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

R<sub>4</sub> is alkyl or alkenyl, which may be interrupted by one or more -O-

10 groups;

5

15

each  $R_3$  is independently H or  $C_{1-10}$  alkyl;

each Y is independently -O- or  $-S(O)_{0-2}$ -;

n is 0 to 4; and

each R present is independently selected from the group consisting of  $C_{1-10}$  alkyl,  $C_{1-10}$  alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof.

- 19. A compound or salt of claim 18 wherein R<sub>2</sub> is H or alkyl.
- 20 20. A compound or salt of claim 18 wherein R<sub>2</sub> is -alkyl-O-alkyl.
  - 21. A compound of the formula (IV):

(IV)

25

wherein:

X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-;

 $\mathbf{R}_{10}$  is selected from the group consisting of heteroaryl and heterocyclyl;

```
\mathbf{R_2} is selected from the group consisting of:
                                -hydrogen;
                                -alkyl;
                                -alkenyl;
                                -aryl;
5
                                -heteroaryl;
                                 -heterocyclyl;
                                 -alkyl-Y-alkyl;
                                 -alkyl-Y-alkenyl;
                                 -alkyl-Y-aryl; and
10
                                 -alkyl or alkenyl substituted by one or more substituents selected
                                 from the group consisting of:
                                          -OH;
                                          -halogen;
                                          -N(R_3)_2;
15
                                          -CO-N(R_3)_2;
                                          -CO-C_{1-10} alkyl;
                                          -CO-O-C<sub>1-10</sub> alkyl;
                                           -N_3;
                                           -aryl;
20
                                           -heteroaryl;
                                           -heterocyclyl;
                                           -CO-aryl; and
                                           -CO-heteroaryl;
                          each R_3 is independently H or C_{1-10} alkyl;
 25
                           each Y is independently -O- or -S(O)<sub>0-2</sub>-;
                           n is 0 to 4; and
                           each {\bf R} present is independently selected from the group consisting of C_{1\text{-}10}
                           alkyl, C_{1-10} alkoxy, hydroxy, halogen and trifluoromethyl;
                           or a pharmaceutically acceptable salt thereof.
```

- 22. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 1 and a pharmaceutically acceptable carrier.
- A pharmaceutical composition comprising a therapeutically effective amount of a
   compound or salt of claim 10 and a pharmaceutically acceptable carrier.
  - 24. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 17 and a pharmaceutically acceptable carrier.
- 25. A method of inducing cytokine biosynthesis in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 1 to the animal.
  - 26. The method of claim 25 wherein the cytokine is IFN-α.
- 15 27. A method of inducing cytokine biosynthesis in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 10 to the animal.
  - 28. The method of claim 27 wherein the cytokine is IFN-α.

- 20 29. A method of treating a viral disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 1 to the animal.
  - 30. A method of treating a neoplastic disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 1 to the animal.
  - 31. A method of treating a viral disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 10 to the animal.
- 32. A method of treating a neoplastic disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 10 to the animal.

- 33. A method of inducing cytokine biosynthesis in an animal comprising administering a theraputically effective amount of a compound or salt of claim 17 to the animal.
- 34. The method of claim 33 wherein the cytokine is IFN- $\alpha$ .
- 35. A method of treating a viral disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 17 to the animal.
- 36. A method of treating a neoplastic disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 17 to the animal.
  - 37. A compound of the formula (V):

$$R_1$$
 $N$ 
 $R_2$ 
 $X-O-R_1$ 
 $X$ 

5

wherein:

X is -CHR<sub>3</sub>-, -CHR<sub>3</sub>-alkyl-, or -CHR<sub>3</sub>-alkenyl-;

 $\mathbf{R_1}$  is selected from the group consisting of:

-heteroaryl;

20

-heterocyclyl;

-R<sub>4</sub>- heteroaryl;

-R<sub>4</sub>-heterocyclyl; and

 $-(CH_2)_{1-10}-C\equiv C-R_{10};$ 

R<sub>2</sub> is selected from the group consisting of:

25

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

```
-heteroaryl;
                                  -heterocyclyl;
                                  -alkyl-Y-alkyl;
                                  -alkyl-Y-alkenyl;
                                  -alkyl-Y-aryl; and
5
                                  - alkyl or alkenyl substituted by one or more substituents selected
                                  from the group consisting of:
                                            -OH;
                                            -halogen;
                                            -N(R_3)_2;
10
                                            -CO-N(R_3)_2;
                                            -CO-C<sub>1-10</sub> alkyl;
                                             -CO-O-C<sub>1-10</sub> alkyl;
                                             -N_3;
                                             -aryl;
 15
                                             -heteroaryl;
                                             -heterocyclyl;
                                              -CO-aryl; and
                                              -CO-heteroaryl;
  20
                             R<sub>4</sub> is alkyl or alkenyl, which may be interrupted by one or more -O-
                             groups;
                             each \mathbb{R}_3 is independently H or \mathbb{C}_{1\text{--}10} alkyl;
                             \mathbf{R}_{10} is heteroaryl or heterocyclyl;
                              each Y is independently -O- or -S(O)_{0-2}-;
   25
                              n is 0 to 4; and
                              each {\bf R} present is independently selected from the group consisting of C_{1\text{-}10}
                              alkyl, C<sub>1-10</sub> alkoxy, hydroxy, halogen and trifluoromethyl;
                               or a pharmaceutically acceptable salt thereof.
```

#### A compound of the formula (VI): 38.

$$R_n$$
 $N$ 
 $R_2$ 
 $X-O-R_1$ 
(VI)

X is -CHR<sub>3</sub>-, -CHR<sub>3</sub>-alkyl-, or -CHR<sub>3</sub>-alkenyl-; wherein: 5

10

15

20

25

 $\mathbf{R}_1$  is selected from the group consisting of:

-heteroaryl;

-heterocyclyl;

-R<sub>4</sub>- heteroaryl;

-R4-heterocyclyl; and

 $-(CH_2)_{1-10}-C\equiv C-R_{10};$ 

 $\mathbf{R_2}$  is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

-alkyl-Y-alkenyl;

-alkyl-Y-aryl; and

- alkyl or alkenyl substituted by one or more substituents selected

from the group consisting of:

-OH;

-halogen;

 $-N(R_3)_2;$ 

 $-CO-N(R_3)_2;$ 

-CO-C<sub>1-10</sub> alkyl;

-CO-O-C<sub>1-10</sub> alkyl;

 $-N_3$ ;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

R<sub>4</sub> is alkyl or alkenyl, which may be interrupted by one or more -O-

groups;

each R<sub>3</sub> is independently H or C<sub>1-10</sub> alkyl;

 $\mathbf{R}_{10}$  is heteroaryl or heterocyclyl;

each Y is independently -O- or -S(O)<sub>0-2</sub>-;

15 n is 0 to 4; and

each R present is independently selected from the group consisting of C<sub>1-10</sub>

alkyl, C<sub>1-10</sub> alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof.

20 39. A compound of the formula (VIII):

(VIII)

wherein:

X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-;

25

5

10

 $\mathbf{R}_1$  is selected from the group consisting of:

-heteroaryl;

-heterocyclyl;

```
-R4- heteroaryl; and
                                -R<sub>4</sub>-heterocyclyl;
                       R<sub>2</sub> is selected from the group consisting of:
                                -hydrogen;
                                -alkyl;
5
                                -alkenyl;
                                 -aryl;
                                 -heteroaryl;
                                 -heterocyclyl;
                                 -alkyl-Y-alkyl;
10
                                 -alkyl-Y-alkenyl;
                                 -alkyl-Y-aryl; and
                                 - alkyl or alkenyl substituted by one or more substituents selected
                                 from the group consisting of:
                                          -OH;
15
                                          -halogen;
                                           -N(R_3)_2;
                                           -CO-N(R_3)_2;
                                           -CO-C_{1-10} alkyl;
                                           -CO-O-C<sub>1-10</sub> alkyl;
 20
                                           -N_3;
                                            -aryl;
                                            -heteroaryl;
                                            -heterocyclyl;
                                            -CO-aryl; and
  25
                                            -CO-heteroaryl;
                            R<sub>4</sub> is alkyl or alkenyl, which may be interrupted by one or more -O-
                            groups;
                            each R_3 is independently H or C_{1-10} alkyl;
                            each Y is independently -O- or -S(O)_{0-2}-;
   30
                            n is 0 to 4;
```

each  $\mathbf{R}$  present is independently selected from the group consisting of  $C_{1-10}$  alkyl,  $C_{1-10}$  alkoxy, hydroxy, halogen and trifluoromethyl; and  $\mathbf{R}_7$  is *tert*-butyl or benzyl; or a pharmaceutically acceptable salt thereof.

5

# 40. A compound of the formula (IX)

$$R_n$$
 $C1$ 
 $N$ 
 $R_2$ 
 $X-O-R_1$ 
 $(IX)$ 

10

15

20

wherein:

X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-;

 $\mathbf{R}_1$  is selected from the group consisting of:

-heteroaryl;

-heterocyclyl;

-R<sub>4</sub>- heteroaryl; and

-R<sub>4</sub>-heterocyclyl;

 $\mathbf{R_2}$  is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

-alkyl-Y-alkenyl;

-alkyl-Y-aryl; and

- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of: -OH;

-halogen;  $-N(R_3)_2;$ 5  $-CO-N(R_3)_2;$ -CO-C<sub>1-10</sub> alkyl; -CO-O-C<sub>1-10</sub> alkyl;  $-N_3$ ; -aryl; 10 -heteroaryl; -heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

R4 is alkyl or alkenyl, which may be interrupted by one or more -O-15 groups;

each  $\mathbb{R}_3$  is independently H or  $\mathbb{C}_{1\text{-}10}$  alkyl; each Y is independently -O- or  $-S(O)_{0-2}$ -;

n is 0 to 4; and

each  ${\bf R}$  present is independently selected from the group consisting of  $C_{1\text{--}10}$ 20 alkyl, C<sub>1-10</sub> alkoxy, hydroxy, halogen and trifluoromethyl; or a pharmaceutically acceptable salt thereof.

- A pharmaceutical composition comprising a therapeutically effective amount of a 41. compound or salt of claim 18 and a pharmaceutically acceptable carrier. 25
  - A method of inducing cytokine biosynthesis in an animal comprising administering 42. a therapeutically effective amount of a compound or salt of claim 18 to the animal.
- The method of claim 42 wherein the cytokine is IFN- $\alpha$ . 43. 30

- 44. A method of treating a viral disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 18 to the animal.
- 45. A method of treating a neoplastic disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 18 to the animal.
  - 46. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 21 and a pharmaceutically acceptable carrier.
- 10 47. A method of inducing cytokine biosynthesis in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 21 to the animal.
  - 48. The method of claim 47 wherein the cytokine is IFN- $\alpha$ .
  - 15 49. A method of treating a viral disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 21 to the animal.
    - 50. A method of treating a neoplastic disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 21 to the animal.

51. A compound of the formula (VII):

(VII)

wherein:

 $\mathbf{Z}$  is NH<sub>2</sub> or NO<sub>2</sub>;

25

X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-;

R<sub>1</sub> is selected from the group consisting of:

-heteroaryl;

-heterocyclyl;

-R4- heteroaryl; and

-R<sub>4</sub>-heterocyclyl;

R<sub>4</sub> is alkyl or alkenyl, which may be interrupted by one or more -Ogroups;

each  $\mathbb{R}_3$  is independently H or  $\mathbb{C}_{1-10}$  alkyl;

n is 0 to 4; and

5

10

20

25

each  ${\bf R}$  present is independently selected from the group consisting of  $C_{1\text{--}10}$ alkyl, C<sub>1-10</sub> alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof.

A compound of the formula (XLIV): 52.

(XLIV)

wherein: 15

X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-;

 $\mathbf{R}_1$  is selected from the group consisting of:

-heteroaryl;

-heterocyclyl;

-R<sub>4</sub>- heteroaryl; and

-R4-heterocyclyl;

R<sub>2</sub> is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

```
-alkyl-Y-alkenyl;
                                -alkyl-Y-aryl; and
                                - alkyl or alkenyl substituted by one or more substituents selected
                                from the group consisting of:
                                         -OH;
5
                                         -halogen;
                                         -N(R_3)_2;
                                         -CO-N(R_3)_2;
                                         -CO-C<sub>1-10</sub> alkyl;
                                         -CO-O-C_{1-10} alkyl;
10
                                          -N_3;
                                          -aryl;
                                          -heteroaryl;
                                          -heterocyclyl;
                                          -CO-aryl; and
15
                                           -CO-heteroaryl;
                          R4 is alkyl or alkenyl, which may be interrupted by one or more -O-
                           groups;
                           each \mathbf{R_3} is independently H or C_{1\text{--}10} alkyl;
                           each Y is independently -O- or -S(O)<sub>0-2</sub>-;
 20
                           n is 0 to 4; and
                           each {\bf R} present is independently selected from the group consisting of C_{1\text{--}10}
                           alkyl, C_{1-10} alkoxy, hydroxy, halogen and trifluoromethyl;
                           or a pharmaceutically acceptable salt thereof.
```